6.92k followers • 31 symbols Watchlist by Yahoo Finance
Follow this list to discover and track large drug and biotechnology companies.
Curated by Yahoo Finance
Follow this list to discover and track large drug and biotechnology companies. These companies develop speciality drugs and treatments for various diseases and medical conditions. Although there are risks associated with the success of the drug, those that succeed tend to have a strong series of earnings growth over a period of time, especially when they are backed by patents.
The list includes stocks priced at $5 or more with a three-month average daily trading volume in excess of 200,000 shares. This list is generated daily and sorted by market cap; the gains are based on the latest closing price and limited to the top 30 stocks that meet the criteria.
This watchlist is similar to a discontinued watchlist called ‘Battling Cancer’.
Yahoo Finance employs sophisticated algorithms to monitor and detect trends in the global financial markets. We bring these insights to you in the form of watchlists.
Find other winning investment ideas with the Yahoo Finance Screener.How are these weighted?
The stocks in this watchlist are weighted equally.
|Watchlist||Change today||1-month return||1-year return||Total return|
|Biotech and drug stocks||+0.63%||-||-||-|
|Symbol||Company name||Last price||Change||% change||Market time||Volume||Avg vol (3-month)||Market cap|
|JNJ||Johnson & Johnson||163.4||+0.04||+0.02%||4:00 pm GMT-5||7.28M||7.12M||427.21B|
|LLY||Eli Lilly and Company||339.68||+2.02||+0.60%||4:03 pm GMT-5||2.45M||2.93M||322.76B|
|NVO||Novo Nordisk A/S||139.59||+1.52||+1.10%||4:00 pm GMT-5||1.06M||1.43M||313.85B|
|MRK||Merck & Co., Inc.||105.68||+1.65||+1.59%||4:03 pm GMT-5||7.90M||9.18M||267.94B|
|ABBV||AbbVie Inc.||145.14||+0.12||+0.08%||4:03 pm GMT-5||5.40M||5.49M||256.68B|
|RHHBY||Roche Holding AG||38.79||+0.44||+1.15%||4:00 pm GMT-5||1.60M||1.41M||253.29B|
|PFE||Pfizer Inc.||43.59||-0.17||-0.39%||4:03 pm GMT-5||22.92M||22.14M||244.68B|
|AZN||AstraZeneca PLC||64.29||+0.77||+1.21%||4:00 pm GMT-5||4.59M||5.12M||199.28B|
|NVS||Novartis AG||86.34||+0.87||+1.02%||4:00 pm GMT-5||3.07M||2.09M||183.01B|
|BMY||Bristol-Myers Squibb Company||74.52||-0.01||-0.01%||4:00 pm GMT-5||8.57M||9.02M||158.44B|
|AMGN||Amgen Inc.||244||+0.15||+0.06%||4:00 pm GMT-5||2.41M||2.66M||130.30B|
|SNY||Sanofi||46.97||+1.11||+2.42%||4:00 pm GMT-5||2.42M||2.50M||119.25B|
|GILD||Gilead Sciences, Inc.||86.05||-0.31||-0.36%||4:00 pm GMT-5||7.30M||7.33M||107.30B|
|REGN||Regeneron Pharmaceuticals, Inc.||769.94||-10.92||-1.40%||4:00 pm GMT-5||885.94k||662.46k||83.85B|
|VRTX||Vertex Pharmaceuticals Incorporated||308.54||+3.67||+1.20%||4:00 pm GMT-5||1.30M||1.44M||79.20B|
|ZTS||Zoetis Inc.||165.57||+0.64||+0.39%||4:03 pm GMT-5||1.72M||2.34M||77.17B|
|GSK||GSK plc||36.17||+0.83||+2.35%||4:00 pm GMT-5||4.04M||5.09M||74.05B|
|MRNA||Moderna, Inc.||171.06||+0.79||+0.46%||4:00 pm GMT-5||2.57M||5.02M||65.72B|
|BAYRY||Bayer Aktiengesellschaft||15.92||+0.26||+1.66%||4:00 pm GMT-5||612.31k||694.95k||62.56B|
|TAK||Takeda Pharmaceutical Company Limited||15.92||+0.12||+0.76%||4:00 pm GMT-5||1.91M||2.84M||49.69B|
|BIIB||Biogen Inc.||291.43||+3.15||+1.09%||4:00 pm GMT-5||802.82k||1.19M||41.97B|
|HLN||Haleon plc||8.18||+0.06||+0.74%||4:00 pm GMT-5||4.16M||6.39M||37.77B|
|BNTX||BioNTech SE||142.115||+1.15||+0.82%||4:00 pm GMT-5||371.87k||900.82k||34.49B|
|ALNY||Alnylam Pharmaceuticals, Inc.||220.95||-3.19||-1.42%||4:00 pm GMT-5||793.18k||760.30k||27.18B|
|BGNE||BeiGene, Ltd.||249.12||+3.94||+1.61%||4:00 pm GMT-5||166.19k||276.06k||26.08B|
|GMAB||Genmab A/S||39.24||+0.31||+0.80%||4:00 pm GMT-5||364.88k||655.75k||25.92B|
|SGEN||Seagen Inc.||137.44||+1.44||+1.06%||4:00 pm GMT-5||598.03k||922.02k||25.52B|
|HZNP||Horizon Therapeutics Public Limited Company||109.8||-0.45||-0.41%||4:00 pm GMT-5||1.66M||4.19M||25.08B|
|ARGX||argenx SE||379.74||+6.45||+1.73%||4:00 pm GMT-5||213.03k||232.09k||21.10B|
|BMRN||BioMarin Pharmaceutical Inc.||111.31||-0.87||-0.78%||4:00 pm GMT-5||1.79M||1.52M||20.69B|
The stock market rallied Tuesday on Fed chief Jerome Powell and a Microsoft AI arms race. Fortinet and Enphase were big winners late.
My name is Susie Lisa, and as the senior vice president of investor relations for Vertex, it is my pleasure to welcome you to our fourth quarter and full year 2022 financial results conference call. On tonight's call, making prepared remarks, we have Dr. Reshma Kewalramani, Vertex' CEO and president; Stuart Arbuckle, chief operating officer; and Charlie Wagner, chief financial officer.
The pharmaceutical giant's next play is a CRISPR-based gene therapy that could launch as soon as this year.